

Injectable Drugs Therapeutics Development and Professional Review Analysis 2018

Injectable Drugs Market 2018 Competitor Information, Analysis, and Insights to Improve R&D Strategies 2023

PUNE, INDIA, March 16, 2018 / EINPresswire.com/ -- Summary

This report is the 6th edition of our long-running analysis of the injectables CMO industry. It provides an expert quantitative analysis on the latest trends and plans for outsourcing commercially approved injectable products. It combines the rich data resources of PharmSource and Pharmaceutical Intelligence Center with our 20 years' experience in analyzing the injectables CMO industry to provide the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.

Scope

- The report is based on the most recent data on industry capacity, the injectables pipeline and the behaviors of the key biopharmaceutical industry actors.

- The model and assumptions are fully explained so you can understand how the analysis was driven and how conclusions were reached.

GET SAMPLE REPORT @ <u>https://www.wiseguyreports.com/sample-request/3066682-pharmsource-demand-and-supply-for-contract-manufacturing-of</u>

Reasons to buy

This 70-page report gives important, expert insight you won't find in any other source. Over 25 tables and graphs throughout the report illustrate major points and trends. This report is required reading for

- CMO executives who must have deep understanding of the injectables marketplace to make strategic planning and investment decisions.

- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Table of Content: Key Points Chapter 1: Executive Summary 1 Chapter 2: Objectives and Methodology 3 Methodology 3 Chapter 3: Recent Trends in Injectables NDA/BLA Approvals 5 Injectables approvals overview 5 NDA/BLA approvals of injectable products 6 Injectable NDA/BLA approvals by sponsor type 10 Processing and packaging characteristics 12 Contract manufacturing of injectable NDA/BLA approvals 15 European biosimilar approvals 18 Cytotoxic drug approvals 19 CMOs winning NDA/BLA approvals 20 What it means 21 Chapter 4: Injectables Pipeline 24 Pipeline Overview 24 Biosimilars 27 Cytotoxic and High Potency Pipeline 28 Pipeline Ownership 29 Pipeline by Route of Administration 31 Unit volumes 32 What it means 35 Chapter 5: Demand Forecast for CMO Capacity 36 ...Continued

ACCESS REPORT @ <u>https://www.wiseguyreports.com/reports/3066682-pharmsource-demand-and-supply-for-contract-manufacturing-of</u>

Get in touch: LinkedIn: <u>www.linkedin.com/company/4828928</u> Twitter: <u>https://twitter.com/WiseGuyReports</u> Facebook: <u>https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts</u>

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.